From theheart.org on Medscape

Coverage from the

Transcatheter Cardiovascular Therapeutics (TCT) 2023

October 23 - 26, 2023; San Francisco, California

October 23 - 26, 2023 San Francisco, California

TCT 2023 Trilogy TAVR Safe, Effective in Aortic Regurgitation The Trilogy transcatheter aortic valve replacement system was safe and effective for high-risk surgical patients with aortic regurgitation, improving LV remodeling and function, in the ALIGN-AR trial.
Medscape Medical News, October 26, 2023
TCT 2023 TAVR With LAAO Non-inferior to TAVR Plus Medical Therapy Left atrial appendage occlusion in the same procedure with transcatheter aortic valve replacement proved non-inferior to TAVR plus medical therapy in AF and aortic stenosis, in the WATCH-TAVR study.
Medscape Medical News, October 25, 2023

Conference News

Transcatheter Tricuspid Repair Improved Quality of Life
Medscape Medical News, December 12, 2023
Amulet and Watchman Equal for Left Atrial Appendage Closure
Medscape Medical News, December 8, 2023
TCT 2023 Transapical Valve Replacement Relieves Mitral Regurgitation
Medscape Medical News, November 30, 2023
TCT 2023 No Harm in Short Aspirin Duration After PCI for ACS
Medscape Medical News, November 7, 2023
TCT 2023 Drug-Coated Balloon Better for High-Risk In-Stent Restenosis
Medscape Medical News, November 3, 2023

TCT 2023 Resorbable Scaffold Beats Angioplasty in Below-Knee CLTI
Medscape Medical News, October 30, 2023
TCT 2023 Low-Risk TAVR Studies: Divergent Long-Term Results
Medscape Medical News, October 26, 2023
TCT 2023 Trilogy TAVR Safe, Effective in Aortic Regurgitation
Medscape Medical News, October 26, 2023
TCT 2023 TAVR With LAAO Non-inferior to TAVR Plus Medical Therapy
Medscape Medical News, October 25, 2023

Popular News from TCT 2022

TAVR Now Used in Almost 50% of Younger Severe AS Patients TAVR rates in patients with aortic stenosis increased in all age groups since 2016, including those younger than 65, even though 2020 valve replacement guidelines recommend surgery in those patients.
Medscape Medical News, Sep 16, 2022
Add PCSK9 Inhibitors to Statins at Primary PCI: EPIC-STEMI The powerful LDL-lowering agents aren't being used to their fullest potential, but giving them early to STEMI patients along with high-intensity statins would help amend that, researchers say.
Medscape Medical News, Sep 22, 2022
Legacy of Neutral SYMPLICITY HTN-3 Recast by Long-term Outcomes Although interest in renal denervation in hypertension fell off after disappointing results from the 2014 trial, a new, longer-term analysis argues the treatment may have 'worked' after all.
Medscape Medical News, Sep 19, 2022

Previous Coverage

Related Resources

Interventional Cardiology & Surgery